Kangbuk Samsung Hospital: "Ultra-Low-Dose Triple Pill Proves Superior for Initial Hypertension Treatment"
Superior Efficacy Over Standard Monotherapy
Proven by the World’s First Phase 3 Clinical Trial
A groundbreaking study has revealed that, for patients beginning hypertension treatment, a single-pill combination therapy comprised of three ingredients at ultra-low doses is more effective and safer than traditional monotherapies. This marks the first time such results have been reported worldwide.
Gi-cheol Sung, Professor of Cardiology at Kangbuk Samsung Hospital. Kangbuk Samsung Hospital
View original imagePreviously, hypertension treatment typically began with a single active ingredient, increasing the dose or adding another agent only if blood pressure was not controlled. However, higher doses raise the risk of adverse effects, and the burden of having to take multiple pills often leads to poor medication adherence among patients.
On July 15, Kangbuk Samsung Hospital announced that Professor Ki-Chul Sung’s cardiology team combined three of the most commonly used antihypertensive drugs—Amlodipine, Losartan, and Chlorthalidone—at approximately one-third of their standard doses into a single pill, resulting in these significant findings. The team monitored 8-week outcomes in patients with mild to moderate hypertension (systolic blood pressure of 140–180 mmHg) at over 20 hospitals in Korea.
The results showed that the ultra-low-dose triple combination was significantly more effective in controlling blood pressure compared to standard-dose Losartan monotherapy, and demonstrated efficacy equivalent to standard-dose Amlodipine monotherapy.
The combination therapy also excelled in safety. Less than 1% of patients experienced serious adverse effects after taking the medication, and not a single case of leg edema—a common side effect of antihypertensive drugs—was reported.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Professor Sung stated, “This phase 3 clinical trial is the first to demonstrate that an ultra-low-dose triple fixed-dose combination is not only more effective but also safe compared to standard monotherapies. By reducing the number of pills and simplifying the complex treatment process for hypertension, we expect this approach to improve the stagnant hypertension control rates.” The study results have been published in the latest issue of the official journal of the American College of Cardiology, ‘JACC’.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.